Persistent and prolonged cough in children: differential diagnosis and treatment algorithms
https://doi.org/10.21518/2079-701X-2019-17-58-75
Abstract
The article presents data on the etiology, modern methods for diagnosis and treatment of respiratory system diseases and examines in detail cough as the main symptom. Particular attention is paid to hypertussivity, which is defined as a cough that occurs in the absence of obvious reasons. In addition, the emphasize was put on the role of anatomical and physiological features in the development and characteristics of cough, especially in young children. The authors draw attention to the complex mechanism of the cough, which development involves many body systems such as nervous, immune, endocrine and respiratory. The article describes the main treatment methods, drugs prescribed to the patients with cough, which are divided into «antitussive» drugs used as cough suppressants and «protussive» drugs used in situations, in which mobilization of secretions is desired, combined drugs. The role of new combined drugs, in particular, Rengalin, which affects the central and peripheral links of the cough reflex, was noted.
About the Authors
Yu. L. Mizernitskiy
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University
Russian Federation
Russian Federation
Yuriy L. Mizernitski, Dr. of Sci. (Med.), Professor, Honoured Healthcare Worker of the Russian Federation, Head of Department of Chronic Inflammatory and Allergic Lung Diseases, Autonomous Subdivision «Veltischev Research and Clinical Institute for Paediatrics», Federal State Budgetary Educational Institution of Higher Education «Pirogov Russian National Research Medical University» of the Ministry of Health of the Russian Federation; Head of Children’s Research Center for Pulmonology of the Russian Healthcare Ministry
2, Taldomskaya St., Moscow, 125412
I. M. Melnikova
Yaroslavl State Medical University
Russian Federation
Russian Federation
Irina M. Melnikova, Dr. of Sci. (Med.), Professor, Head of Chair for Hospital Paediatrics
5, Revolyutsionnaya St., Yaroslavl, 150000
References
1. Kantar A. Phenotypic presentation of chronic cough in children. Journal of Thoracic Disease. 2017;9(4):907-913. doi: 10.21037/jtd.2017.03.53.
2. Marchant J.M., Newcombe P.A., Juniper E.F., Sheffield J.K., Stathis S.L., Chang A.B. What is the burden of chronic cough for families? Chest. 2008;134:303-309. doi: 10.1378/chest.07-2236.
3. Melnikova I.M., Udaltsova E.V., Mizernitskiy Y.L. Algorithms for differential diagnosis of diseases accompanied by protracted and chronic cough in children. Pediatria. 2018;97(2):8-18. (In Russ.) doi: 10.24110/0031-403X-2018-97-2-8-18.
4. Rhee C.K., Jung J.Y., Lee S.W., Kim J.H., Park S.Y., Yoo K.H., Park D.A., Koo H.K., Kim Y.H., Jeong I., Kim J.H., Kim D.K., Kim S.K., Kim Y.H., Park J., Choi E.Y., Jung K.S., Kim H.J. The Korean Cough Guideline: Recommendation and Summary Statement. Tuberc Respir Dis (Seoul). 2016;79(1):14-21. doi: 10.4046/trd.2016.79.1.14.
5. Gibson P.G., Chang A.B., Glasgow N.J., Holmes P.W., Katelaris P., Kemp A.S., Louis Landau, Mazzone S., Newcombe P., Asperen P. Van, Vertigan A.E. CICADA: Cough in Children and Adults: Diagnosis and Assessment. Australian cough guidelines summary statement. Medical Journal of Australia. 2010;192(5):265-271. doi: 10.5694/j.1326-5377.2010.tb03504.x.
6. Irwin R.S., French C.T., Lewis S.Z., Diekemper R.L., Gold P.M. CHEST Expert Cough Panel. Overview of the Management of Cough: CHEST Guideline and Expert Panel. Report. Chest. 2014;146(4):885-889. doi: 10.1378/chest.141485.
7. Morice A.H., Fontana G.A., Belvisi M.G., Birring S.S., Chung K.F., Dicpinigaitis P.V., Kastelik J.A., McGarvey L.P., Smith J.A., Tatar M., Widdicombe J. ERS guidelines on the assessment of cough. European Respiratory Journal. 2007;29(6):12561276. doi: 10.1183/09031936.00101006.
8. Usta G.B., Asilsoy S., Durmaz C. The assessment and management of chronic cough in children according to the British Thoracic Society guidelines: descriptive, prospective, clinical trial. Clin Respiratory Journal. 2014;8(3):330-337. doi.org/10.1111/crj.12076.
9. Blokhin B.M., Lobushkova I.P., Roshchina A.K., Kuznetsov A.Yu., Mirzoev T.Kh. Diagnosis, management and treatment for cough in children. RMJ = Russian Medical Juournal. 2015;23(3):169173. (In Russ.) Available at: https://www.rmj.ru/articles/pediatriya/Diagnostika_taktika_i_metody_lecheniya_kashlya_u_detey/
10. Crotty A.L.E., Shin S., Hwang J.H. Inflammatory Diseases of the Lung Induced by Conventional Cigarette Smoke: A Review. Chest. 2015;148(5):1307-1322. doi: 10.1378/chest.150409.
11. Chikina S.Yu., Belevskiy A.S. Cough: New Conception and New Therapy. Russian Pulmonology. (In Russ.). Available at: https://elibrary.ru/download/elibrary_27187211_69855935.pdf.
12. Chang A.B., Glomb W.B. Guidelines for evaluating chronic cough in pediatrics: ACCP evidencebased clinical practice guidelines. Chest. 2006;129:260-283. doi: 10.1378/chest.129.1_suppl.260S.
13. Melnikova I.M., Udaltsova E.V., Mizernitskiy Y.L. Algorithms for differential diagnosis of diseases accompanied by protracted and chronic cough in children. Pediatriya = Pediatria. 2018;97(2):8-18. (In Russ.) doi: 10.24110/0031403X-2018-97-2-8-18.
14. Song W.-J., Chang Y.-S., Morice A. H. Changing the paradigm for cough: does «cough hypersensitivity » aid our understanding? Asia Pac Allergy. 2014;4(1):3-13. doi: 10.5415/apallergy.2014.4.1.3.
15. Simonova O.I. Cough in children: peculiarities of pathogenesis and treatment. Voprosy sovremennoy pediatrii = Current Pediatrics. 2012;11(3):34-42. (In Russ.) doi: 10.15690/vsp.v11i3.294.
16. Tatochenko V.K. Differential diagnosis and treatment of cough in children. Lechashchiy vrach = Attending Doctor. 2008;3:60-66. (In Russ.) Available at: https://www.lvrach.ru/2008/03/4910226/
17. Yilmaz O., Bakirtas A., Ertoy Karagol H.I. et al. Children with chronic nonspecific isolated cough. Chest. 2014;145(6):1279-1285. doi: 10.1378/chest.13-2348.
18. Panyakina M.A. Post-infectious cough: modern view on pathogenesis and treatment options. Vestnik Otorinolaringologii = Bulletin of Otorhinolaryngology. 2013;4:78-81. (In Russ.) Available at: https://mediasphera.ru/issues/vestnik-otorinolaringologii/2013/4/downloads/ru/030042-46682013417.
19. Kazachkov M. Etiology and differential diagnosis of chronic cough in children. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2013;58(3):154-161. (In Russ.) Available at: https://cyberleninka.ru/article/v/etiologiya-idifferentsialnyydiagnoz-hronicheskogo-kashlyau-detey.
20. Pirogowicz I., Patyk M., Popecki P., Rudnicki J., Gojny L., Pokorski M. Lung Function in Patients with Gastro-Esophageal Reflux Disease and Respiratory Symptoms. In: Pokorski M. (eds). Neurobiology of Respiration. Advances in Experimental Medicine and Biology. 2013;788:161-166. doi.org/10.1007/978-94007-6627-3_24.
21. Privorotskiy V.F., Luppova N.E., Bel’mer S.V., Apenchenko Yu.S., Basalaeva N.V., Gurova M.M., Zvyagin A.A., Kamalova A.A., Kornienko E.A., Myzin A.V., Gerasimova N.V., Moiseev A.B., Nizhevich A.A., Pechkurov D.V., Semin S.G., Sitnikova E.A., Dublina E.S., Khavkin A.I., Shcherbakov P.L., Erdes S.I. Pediatric Gastroesophageal Reflux Clinical Practice Guideline. Detskaya Bol’nitsa = Children Hospital. 2014;1(55):54-61. (In Russ.) Available at: https://elibrary.ru/download/elibrary_21345809_90768411.pdf.
22. Rosen R., Vandenplas Y., Singendonk M., Cabana M., DiLorenzo C., Gottrand F., Gupta S., Langendam M., Staiano A., Thapar N., Tipnis N., Tabbers M. North American Society for Pediatric Gastroenterology Hepatology and Nutrition, European Society for Pediatric Gastroenterology Hepatology and Nutrition. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Journal of Pediatric Gastroenterology and Nutrition. 2009;49(4):498-547. doi: 10.1097/MPG.0000000000001889.
23. Udal’tsova E.V., Mel’nikova I.M., Mizernitskiy Yu.L., Grigor’eva E.A. Clinical aspects of persistent and chronic cough of psychogenic origin in children. Ural’skiy Meditsinskiy Zhurnal = Ural Medical Journal. 2017;5(149):40-45. (In Russ). Available at: https://elibrary.ru/item.asp?id=29381367.
24. Milazzo L., Cattaneo D., Cheli S., Ferraris L., Colella E., Clementi E., Gervasoni C. ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor? Eur J Clin Pharmacol. 2013;69(3):743-745. doi: 10.1007/s00228-012-1397-0.
25. Lerkhendorf Yu.A., Lukina O.F, Petrenets T.N., Delyagin V.M. Bronchophonography in children aged 2 to 7 years old with bronchial obstructive syndrome. Prakticheskaya meditsina = Practical medicine. 2017;2(103):134-137. (In Russ.) Available at: https://elibrary.ru/download/elibrary_29044753_38921182.pdf.
26. National program: Bronchial asthma in children. Strategy for asthma management and prevention. 5th edition updated and revised. Moscow: Original-maket; 2017.160 p. (In Russ.) Available at: http://nphcd.ru/wp-content/uploads/2017/05/103640_old.pdf.
27. Brand P.L.P., Caudri D., Eber E., Gaillard E.A., Garcia-Marcos L., Hedlin G., Henderson J., Kuehni C. E., Merkus P.J.F.M., Pedersen S., Valiulis A., Wennergren G., Bush A. Classification and pharmacological treatment of preschool wheezing: changes since 2008. European Respiratory Journal. 2014;43(4):11721177. doi: 10.1183/09031936.00199913.
28. Murray C.S., Woodcock A., Langley S.J., Morris J., Custovic A. Secondary prevention of asthma by the use of inhaled fluticasone propionate in wheezy infants (IFWIN): double-blind, randomised, controlled study. Lancet. 2006;368:754-762. doi: 10.1016/S01406736(06)69285-4.
29. Avdeev S.N. Use of nebulizers in clinical practice. RMJ = Russian Medical Journal. 2001;(5):189 (In Russ.) Available at: https://www.rmj.ru/articles/pulmonologiya/Ispolyzovanie_nebulayzerov_v_klinicheskoy_praktike/
30. Rogers D.F. Mucoactive agents for airway mucus hypersecretory diseases. Respir Care. 2007;52(9):1176-1193. Режим доступа: https://www.ncbi.nlm.nih.gov/pubmed/17716385.
31. Mel’nikova I.Yu., Mizernitskiy Yu.L. Expectorant and mucolytic therapy for acute and chronic bronchopulmonary diseases in children. Prakticheskaya Meditsina = Practical Medicine. 2014;85(9):76-81. (In Russ.) Available at: http://pmarchive.ru/otxarkivayushhaya-imukoliticheskayaterapiya-pri-ostryx-i-xronicheskixbronxolegochnyx-zabolevaniyax-udetej/
32. Mel’nikova I.M., Mizernitskiy Yu.L., Batozhargalova B.Ts., Loginevskaya Ya.V. Modern principles of mucolytic therapy in children with acute and chronic bronchopulmonary diseases. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2011;56(2):45-50. (In Russ.) Available at: https://elibrary.ru/download/elibrary_16375660_92836587.pdf.
33. Elkins M.R., Robinson M., Rose B.R., Harbour C., Moriarty C. P., Marks G. B., Belousova E. G., Xuan W., Bye P.T.P. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. The New England Journal of Medicine. 2006;354:229-240. doi: 10.1056/NEJMoa043900.
34. Sandberg K., Fellman V., Stigson L., Thiringer K.,• Hjalmarson O. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate. 2004;86:275-279. doi.org/10.1159/000080089.
35. Velikova E.R. Prospects for the use of acetylcysteine in therapeutic practice. RMJ. Bolezni Dykhatel’nykh Putey. Otorinolaringologiya. = Russian Medical Journal. Respiratory Diseases. Otorhinolaryngology. 2010;18(7). (In Russ.) Available at: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/O_vozmoghnostyah_primeneniya_acetilcisteina__v_terapevticheskoy_praktike/
36. Tolstova V., Kapranov N. cystic fibrosis: present day aspects of diagnostics and treatment. Pediatricheskaya farmakologiya = Pediatric pharmacology. 2006;3(4):50-55. (In Russ.) Available at: https://pf.spr-journal.ru/jour/article/view/581.
37. Mizernitskiy Yu.L., Mel’nikova I.M. Role of combination mucolytic therapy in infectious and inflammatory diseases of the respiratory tract in children. Meditsinskiy Sovet = Medical Council. 2019;11:56-59. (In Russ.) doi: 10.21518/2079701X-2019-11-56-59.
38. Gembitskaya T.E., Kovaleva L.F. Disorders of mucociliary clearance in patients with chronic respiratory diseases. Spravochnik Poliklinicheskogo Vracha = Outpatient Physician Reference. 2009;(10):31-34. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21951209.
39. Witchurch C.B., Tolker-Nielsen T., Ragas P.C., Mattick J.S. Extracellular DNA required for bacterial biofilm formation. Science. 2002;295:1487. doi: 10.1126/science.295.5559.1487.
40. Robinson P. Dornase alfa in early CF lung disease. Pediatric Pulmonology. 2002;34:237-241. doi: 10.1002/ppul.10136.
41. Selimovic A., Saracevic E., Mujicic E., Dizdarevic A. Treatment of Pseudomonas aeruginosa in cystic fibrosis in a child. Med Arh. 2006;60(1):68-69. Available at: https://www.ncbi.nlm.nih.gov/pubmed/16425540.
42. Simonova O.I. Special warnings and precautions for use of dornase alpha and kinesitherapy in children with cystic fibrosis. Pediatricheskaya Farmakologiya = Pediatric Pharmacology. 2013;10(4):73–78. (In Russ.) Available at: https://elibrary.ru/download/elibrary_20297665_11609170.pdf.
43. Pavlinova E., Mingairova A., Safonova T., Korneyeva T. Estimation of the modern mucolytic therapy efficacy in children, suffering from mucoviscidosis (two year experience of dornase alfa application). Current Pediatrics. 2007;6(2):102-106. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/1058.
44. Brand P.L.P., Caudri D., Eber E., Gaillard E.A. et al. Classification and pharmacological treatment of preschool wheezing: changes since 2008. Eur Respir J. 2014;43(4):1172-1177. doi: 10.1183/09031936.00199913.
45. Volkov I.K. Prospects for the use of dornase alfa in pediatric respiratory medicine. Pul’monologiya = Pulmonology. 2011;(5):97-102. (In Russ.) doi: 10.18093/0869-0189-2011-0-597-102.
46. Romanenko N.I., Kondyurina E.G., Sultanova I.V. et al. Experience of prolonged use of mucolytic dornase alpha at the center for diagnosis, treatment, rehabilitation and medical and social adaptation of patients with cystic fibrosis in Novosibirsk. Voprosy Sovremennoy Pediatrii = Issues of modern pediatrics. 2006;5(2):56-58. (In Russ.) Available at: https://cyberleninka.ru/article/v/opyt-dlitelnogoprimeneniyamukoliticheskogo-preparata-dornazyalfa-v-tsentre-diagnostiki-lecheniya-reabilitatsiii-mediko-sotsialnoy.
47. Rubin B.K. Mucolytics, expectorants, and mucokinetic medications. Respir Care. 2007;52(7):859-865. Available at: https://www.ncbi.nlm.nih.gov/pubmed/17594730.
48. Samsygina G.A. Prolonged cough in children: causes, pathogenesis and principles of therapy. Pediatriya = Pediatrics 2005;5:85-91. (In Russ.) Available at: http://pediatriajournal.ru/files/upload/mags/276/2005_5_1684.pdf.
49. Geppe N.A., Snegotskaya M.N. Role of mucoregulators in treating bronchopulmonary diseases in children. Farmateka = Pharmateca. 2004;17:35-39. (In Russ.) Available at: https://pharmateca.ru/ru/archive/article/5823.
50. Zykov K.A. Prospects for the use of ambroxol in pulmonology. Spravochnik Poliklinicheskogo Vracha = Outpatient Physician Reference. 2009;(3):36-38. (In Russ.) Available at: https://elibrary.ru/item.asp?id=21858408.
51. Gibbs B.F. Differential modulation of IgEdependent activation of human basophils by ambroxol and related secretolytic analogues. Int J Immunopathol Pharmacol. 2009;22(4):919927. doi: 10.1177/039463200902200407.
52. Pfeifer S., Zissel G., Kienst K., MullerQuernheim J. Reduction of cytokine release of blood bronchoalveolar mononuclear cells by ambroxol. Eur J Res. 1997;2(3):129-32. Available at: https://www.ncbi.nlm.nih.gov/pubmed/9113503.
53. Zaplatnikov A.L., Glukhareva N.S., Karoid N.V., Mingalimova A.A., Dmitrieva Yu.A. Mucolytic agents in the combination therapy of children with acute infectious and inflammatory diseases of the respiratory tract. Consilium Medicum Ukraina. 2011;(15):4-8. (In Russ.) Available at: http://www.consilium-medicum.com.ua/issues/1/82/652/
54. Fashner J., Ericson K., Werner S. Treatment of the common cold in children and adults. American Family Physician. 2012;86(2):153-159. Available at: https://www.aafp.org/afp/2012/0715/p153.html.
55. Guyatt G.H., Townsend M., Kazim F., Newhouse M.T. A controlled trial of ambroxol in chronic bronchitis. Chest. 1987;92(4):618–620. doi: 10.1378/chest.92.4.618.
56. Mizernitsky Y.L. Carbocysteines in the current therapy of lung diseases in children. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2016;61(5):19-22. (In Russ.) doi: 10.21508/1027-4065-2016-61-5-19-22.
57. Yoshida M., Nakayama K., Yasuda H., Kubo H., Kuwano K., Arai H., Yamaya M. Carbocisteine inhibits oxidant-induced apoptosis in cultured human airway epithelial cells. Respirology. 2009;14(7):1027-1034. doi: 10.1111/j.1440-1843.2009.01594.x.
58. Novikov Yu.K. Respiratory epithelial clearance as the main lung defense mechanism. RMJ = Russian Medical Journal. 2007;15(5):357-360. (In Russ.) Available at: https://www.rmj.ru/articles/pulmonologiya/Mukociliarnyy_transport_kak_osnovnoy_mehanizm_zaschity_legkih/
59. Ishiura Y., Fujimura M., Yamamori C., Nobata K., Myou S., Kurashima K., Michishita Y., Takegoshi T. Effect of carbocysteine on cough reflex to capsaicin in asthmatic patients. Br J Clin Pharmacol. 2003;55(6):504-510. doi: 10.1046/j.1365-2125.2003.01788.x.
60. Sumitomo T., Nakata M., Yamaguchi M., Terao Y., Kawabata S. S-carboxymethylcysteine inhibits adherence of Streptococcus pneumoniae to human alveolar epithelial cells. J Med Microbiol. 2012;61(1):101-108. doi: 10.1099/jmm.0.033688-0.
61. Mizernitskiy Yu.L., Ermakova I.N. Modern mucoactive agents in the therapy of acute respiratory infections in children. Pediatriya. Prilozhenie Consilium medicum = Pediatrics. Consilium Medicum Supplement. 2007;1:53-56. (In Russ.) Available at: http://old.consilium-medicum.com/media/pediatr/07_01/53.shtml.
62. Maccio A., Madeddu C., Panzone F., Mantovani G. Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. Expert Opin Pharmacother. 2009;10(4):693–703. doi: 10.1517/14656560902758343.
63. Balyasinskaya G.L., Timakov E.Yu. Experience of using Flutitec in treatment of acute obstructive bronchitis in young children. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2010;55(4):45-49. (In Russ.) Available at: https://elibrary.ru/download/elibrary_15254218_69100625.pdf.
64. Brandolini L., Allegretti M., Berdini V., Cervellera M.N., Mascagni P., Rinaldi M., Melillo G., Ghezzi P., Mengozzi M., Bertini R. Carbocysteine lysine salt monohydrate (SCMC-LYS) is a selective scavenger of reactive oxygen intermediates (ROIs). Eur Cytokine Netw. 2003;14(1):20-26. Available at: https://www.ncbi.nlm.nih.gov/pubmed/12799210.
65. Mizernitskiy Yu.L., Mel’nikova I.M., Batozhargalova B.Ts., Loginevskaya Ya.V., Kozlova L.A. Clinical efficacy of carbocysteine lysine salt therapy for acute and chronic bronchopulmonary diseases in children. Voprosy Prakticheskoy Pediatrii = Issues of Practical Pediatrics. 2011;6(5):69-74. (In Russ.) Available at: https://elibrary.ru/download/elibrary_17010545_11745126.pdf.
66. Braga P.C., Dal Sasso M., Culici M., Galastri L., Marceca M.T., Guffanti E.E, Antioxidant potential of thymol determined by chemiluminescence inhibition in human neutrophils and cell-free systems. Pharmacology. 2006;76(2):61-68. doi: 10.1159/000089719.
67. Privalova T.E., Shadrin S.A., Shadrina E.M. New herbal preparations in the treatment of cough in children of younger age range with acute respiratory diseases. Voprosy Sovremennoy Pediatrii = Issues of Modern Pediatrics. 2007;6(4):128-131. (In Russ.) Available at: https://elibrary.ru/download/elibrary_11666047_60084969.pdf.
68. Mizernitskiy Yu.L., Sulaymanov Sh.A. Modern combined herbal preparations in the pulmonology practice. Meditsinskiy Sovet = Medical Council. 2019;(11):82-88. (In Russ.) doi: 10.21518/2079-701X-2019-11-82-88.
69. Mizernitskiy Yu.L. Efficacy and safety of dry ivy extract (Prospan®) in the treatment of bronchitis in children (based on the results of observational ProSpiro study). Pediatriya = Pediatrics. 2019;98(2):119–126. (In Russ.) doi: 10.24110/0031-403X-2019-98-2-119-126.
70. Ovsyannikova E.M., Korovina N.A., Zakharova I.N., Yurkiv I.Ya. Efficacy and tolerance of Prospan in the treatment of inflammatory diseases of the respiratory tract in children (based on the multicenter study results). Pediatriya = Pediatrics. 2007;86(5):88-93. (In Russ.) Available at: https://pediatriajournal.ru/files/upload/mags/286/2007_5_1954.pdf.
71. Trute A., Gross J., Mutschler E., Nahrstedt A. In vitro antispasmodic compounds of the dry extract obtained from Hedera helix. Planta Medica. 1997;63(2):125-129. doi: 10.1055/s-2006-957627.
72. Sarrell E.M., Tal G., Witzling M., Someck E., Houri S., Cohen H.A., Mandelberg A. Nebulized 3% hypertonic saline solution treatment in ambulatory children with viral bronchiolitis decreases symptoms. Chest. 2002;122:2015-2020. doi: 10.1378/chest.122.6.2015.
73. Ballmann M., von der Hardt H. Hypertonic saline and recombinant human DNase: a randomised cross-over pilot study in patients with cystic fibrosis. J Cyst Fibros. 2002;1(1):35-37. Available at: https://www.ncbi.nlm.nih.gov/pubmed/15463808.
74. Zaytsev A.A., Sinopal’nikov A.I. Rational pharmacotherapy for acute respiratory viral infections. Consilium Medicum. 2008;(10):80-86. (In Russ.) Available at: https://con-med.ru/magazines/consilium_medicum/consilium_medicum-10-2008/ratsionalnaya_farmakoterapiya_ostrykh_respiratornykh_virusnykh_infektsiy/
75. Zaitseva S.V., Lokshina E.E., Zaitseva O.V., Muratazaeva O.A., Kuznetsov G.B., Ravshanova L.S., Romanovskaya Zh.A., Khmelkova I.I., Voronina O .B., Rubtsova T.P. Rational choice for treatment of dry cough in children with acute diseases of the lower respiratory tract. Pediatriya = Pediatrics. 2012;91(5):79-85. (In Russ.) Available at: http://pediatriajournal.ru/files/upload/mags/325/2012_5_3511.pdf.
76. Mizernitskiy Yu.L., Mel’nikova I.M. A modern paradigm for managing patients with cough. Meditsinskiy Sovet. Pul’monologiya = Medical Council. Pulmonology. 2016;(15):67-71. (In Russ.)doi: 10.21518/2079701X-2016-15-67-71.
77. Mizernitskiy Yu.L., Mel’nikova I.M., Dorovskaya N.L. Antitussive therapy alternatives in children with acute respiratory infections. Voprosy Prakticheskoy Pediatrii = Issues of Practical Pediatrics. 2019;14(2):68–72. (In Russ.) doi: 10.20953/1817-7646-2019-2-68-72.
78. Geppe N.A., Spasskiy A.A. Results of the All-Russian Non-Interventional Observational Program for the Study of Rengalin in the Outpatient Management of Cough (REAL). Terapiya = Therapy. 2018;(3):134-143. (In Russ.) Available at: https://therapy-journal.ru/ru/archive/article/36230.
79. Mizernitskiy Yu.L., Mel’nikova I.M. Differentiated mucolytic therapy for acute and chronic bronchopulmonary diseases in pediatric practice. Rossiyskiy Vestnik Perinatologii i Pediatrii = Russian Bulletin of Perinatology and Pediatrics. 2016;61(4):23-30. (In Russ.) doi: 10.21508/1027-4065-2016-61-4-23-30.
Review
For citations:
Mizernitskiy YL, Melnikova IM. Persistent and prolonged cough in children: differential diagnosis and treatment algorithms. Meditsinskiy sovet = Medical Council. 2019;(17):58-75. (In Russ.) https://doi.org/10.21518/2079-701X-2019-17-58-75
Views:
1525
Email this article 